Should I buy or sell Vincerx Pharma stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares. View VINC analyst ratings or view top-rated stocks .

What is Vincerx Pharma's stock price target for 2024?

1 Wall Street research analysts have issued 12-month price targets for Vincerx Pharma's stock. Their VINC share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 455.6% from the stock's current price. View analysts price targets for VINC or view top-rated stocks among Wall Street analysts .

How have VINC shares performed in 2024?

Vincerx Pharma's stock was trading at $1.18 at the beginning of the year. Since then, VINC shares have decreased by 23.7% and is now trading at $0.90. View the best growth stocks for 2024 here .

When is Vincerx Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our VINC earnings forecast .

How were Vincerx Pharma's earnings last quarter?

Vincerx Pharma, Inc. (NASDAQ:VINC) issued its earnings results on Thursday, August, 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.18.

How do I buy shares of Vincerx Pharma?

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VINC

Vincerx Pharma (VINC) Stock Price, News & Analysis

→ New crypto project uncovers 2,050% in 65 days (From InvestorPlace) (Ad)

Free VINC Stock Alerts

$0.90

-0.05 (-5.26%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.85
▼
$0.95
50-Day Range: $0.87
▼
$8.06
52-Week Range: $0.61
▼
$9.37

Volume: 531,096 shs
Average Volume: 1.68 million shs
Market Capitalization: $19.27 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.00

Get Vincerx Pharma alerts:

Vincerx Pharma MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 455.6% Upside
$5.00 Price Target
Short Interest: Healthy
5.94% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.01
Based on 2 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.97) to ($1.11) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.21 out of 5 stars

Medical Sector

524th out of 918 stocks

Pharmaceutical Preparations Industry

232nd out of 410 stocks

3.5

Analyst's Opinion

Consensus Rating
Vincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vincerx Pharma has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.94% of the float of Vincerx Pharma has been sold short.
Short Interest Ratio / Days to Cover
Vincerx Pharma has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vincerx Pharma has recently decreased by 7.39%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Vincerx Pharma does not currently pay a dividend.
Dividend Growth
Vincerx Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VINC.

1.7

News and Social Media Coverage

News Sentiment
Vincerx Pharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Vincerx Pharma this week, compared to 1 article on an average week.
Search Interest
93 people have searched for VINC on MarketBeat in the last 30 days. This is an increase of 323% compared to the previous 30 days.
MarketBeat Follows
Only 5 people have added Vincerx Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vincerx Pharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
20.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Vincerx Pharma are expected to decrease in the coming year, from ($0.97) to ($1.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vincerx Pharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vincerx Pharma is -0.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vincerx Pharma has a P/B Ratio of 1.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Vincerx Pharma Stock (NASDAQ:VINC)

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

VINC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VINC Stock News Headlines

April 16, 2024 | americanbankingnews.com

Analyzing Revelation Biosciences (NASDAQ:REVB) and Vincerx Pharma (NASDAQ:VINC)

April 12, 2024 | finance.yahoo.com

Agendia’s BluePrint Included in German Oncology Group Guidelines

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 10, 2024 | finance.yahoo.com

The Rise of Zyn: The Oral Nicotine Product Going Viral

April 10, 2024 | markets.businessinsider.com

Vincerx Pharma Inc (VINC) Gets a Buy from Leerink Partners

April 10, 2024 | americanbankingnews.com

Vincerx Pharma's (VINC) "Overweight" Rating Reaffirmed at Cantor Fitzgerald

April 9, 2024 | msn.com

ACOR, HUBC and DATS among pre-market losers

April 9, 2024 | msn.com

Vincerx in selloff after early-stage data for cancer therapy

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 9, 2024 | investorplace.com

Why Is Vincerx Pharma (VINC) Stock Down 64% Today?

April 8, 2024 | globenewswire.com

Vincerx Pharma Presents Positive Preliminary Phase 1 Data for VIP236 and Updates on Pipeline Progress at the American Association for Cancer Research (AACR) Annual Meeting 2024

April 2, 2024 | investorplace.com

VINC Stock Earnings: Vincerx Pharma Beats EPS for Q4 2023

April 1, 2024 | finanznachrichten.de

Vincerx Pharma, Inc.: Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

April 1, 2024 | finance.yahoo.com

Vincerx to Host Virtual Investor Event Reviewing Preliminary Phase 1 VIP236 Data Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 29, 2024 | finance.yahoo.com

Vincerx Pharma Inc (VINC) Reports Q4 and Full Year 2023 Financials: A Close Look

March 29, 2024 | marketwatch.com

Vincerx Pharma Cuts Funding-Sufficiency View to 3Q From Late 2024

March 29, 2024 | globenewswire.com

Vincerx Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

March 19, 2024 | edition.cnn.com

Vincerx Pharma Inc

March 12, 2024 | benzinga.com

Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

March 7, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vincerx Pharma Ahead of AACR Presentation: Promising Developments in Oncology Drug Pipeline

March 5, 2024 | globenewswire.com

Vincerx to Present Three Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024

March 5, 2024 | finance.yahoo.com

Vincerx Pharma, Inc.'s (NASDAQ:VINC) large institutional owners must be happy as stock continues to impress, up 28% over the past week

February 22, 2024 | morningstar.com

Vincerx Pharma Inc Ordinary Shares VINC

February 22, 2024 | benzinga.com

Vincerx Pharma Stock (NASDAQ:VINC) Dividends: History, Yield and Dates

January 10, 2024 | msn.com

Vincerx Pharma stock rises on positive efficacy data from lymphoma therapy

January 8, 2024 | msn.com

Why Is Cancer Focused Penny Stock Vincerx Pharma Trading Higher Today?

January 8, 2024 | marketwatch.com

Vincerx Pharma Shares Surge Following Early Results for Relapsed, Refractory Lymphoma

See More Headlines

Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/12/2021
Today: 4/18/2024
Next Earnings (Estimated): 5/09/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:VINC
CUSIP: N/A
CIK: 1796129
Web: vincerapharma.com
Phone: 650-800-6676
Fax: N/A
Employees: 41
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.00
High Stock Price Target: $5.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +455.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.89)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-40,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -187.73%
Return on Assets: -126.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.63
Quick Ratio: 2.63

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.52 per share
Price / Book: 1.73

Miscellaneous

Outstanding Shares: 21,410,000
Free Float: 17,002,000
Market Cap: $19.27 million
Optionable: Not Optionable
Beta: 1.10

7 Stocks to Buy And Hold Forever

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

Dr. Ahmed M. Hamdy M.D. (Age 59)
Founder, Chairman & CEO
Comp: $609.84k
Dr. Raquel E. Izumi Ph.D. (Age 54)
Founder, President, COO, Secretary & Director
Comp: $551.66k
Mr. Alexander A. Seelenberger M.B.A. (Age 45)
Chief Financial Officer
Comp: $458.03k
Mr. Tom C. Thomas J.D. (Age 65)
Founder, General Counsel & Chief Legal Officer
Comp: $444.14k
Dr. John C. Byrd M.D.
Founder & Chairman of Scientific Advisory Board
Dr. Hans-Georg Lerchen Ph.D.
Chief Scientific Officer
Ms. Gabriela Jairala
Sr Executive Director of Investor Relations & Corporate Communications
Ms. Karen Quarford
Vice President of Quality Operations & Compliance
Ms. Melissa Merrick SPHR
Senior Director of People & Culture and Head of Human Resource
Dr. Beatrix Stelte-Ludwig Ph.D.
Executive Chief Development Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VINC Stock Analysis - Frequently Asked Questions

Should I buy or sell Vincerx Pharma stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vincerx Pharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" VINC shares.
View VINC analyst ratings or view top-rated stocks.
What is Vincerx Pharma's stock price target for 2024?: 1 Wall Street research analysts have issued 12-month price targets for Vincerx Pharma's stock. Their VINC share price targets range from $5.00 to $5.00. On average, they predict the company's share price to reach $5.00 in the next year. This suggests a possible upside of 455.6% from the stock's current price.
View analysts price targets for VINC or view top-rated stocks among Wall Street analysts.
How have VINC shares performed in 2024?: Vincerx Pharma's stock was trading at $1.18 at the beginning of the year. Since then, VINC shares have decreased by 23.7% and is now trading at $0.90.
View the best growth stocks for 2024 here.
When is Vincerx Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our VINC earnings forecast.

How were Vincerx Pharma's earnings last quarter?: Vincerx Pharma, Inc. (NASDAQ:VINC) issued its earnings results on Thursday, August, 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.18.
How do I buy shares of Vincerx Pharma?: Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VINC) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vincerx Pharma (VINC) Stock Price, News & Analysis

Vincerx Pharma MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vincerx Pharma Stock (NASDAQ:VINC)

VINC Stock Price History

VINC Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VINC Stock Analysis - Frequently Asked Questions

Overall MarketRank^™